12 2023
Benefit from a robust mixed leukocyte reaction assay ...
Considering the importance of dendritic cells in fine-tuning T cell response, their ...Read more
-
Explicyte to present three postersat the AACR Annual Meeting 2023
-
Integrated Histology For Quantitative Digital PathologyHistology Services
-
Olink proteomics joins our biomarker discovery capacitiesAs Olink®-certified service Provider, Explicyte offers now high proteomic analysis capabilities.
-
Spotlight onadenosine-mediated suppression of dendritic cell function
-
Spotlight on our in vivo advancesDevelopment and characterization of a novel anti-PD1 resistant sarcoma mouse model
Preclinical services CRO for drug discovery
Explicyte Immuno-Oncology
We test novel drugs in validated in vitro and in vivo tumor models of cancer immunotherapies and analyze the anti-tumor immune response.
Explicyte immuno-oncology offers preclinical contract research services for cancer immunotherapy drug discovery. Our preclinical CRO services range from cell-based assays - for the phenotypic screening of novel immunotherapeutics and the in vitro determination of the molecular mechanism of action of new anti-cancer immune modulators - to in vivo studies, using syngeneic mouse tumor models treated with antitumor immunotherapies such as immune checkpoint inhibitors (anti CTLA-4 monoclonal antibodies, anti PD1/PDL-1 antibody therapy and IDO/TDO inhibitors). Furthermore, we offer to explore the in vivo mechanism of action of innovative immunotherapies such as anti-cancer vaccines through the profiling of the anti-tumor immune response by flow cytometry, high-content imaging and RT-qPCR. All our drug development services for cancer immunotherapy are performed in Bordeaux, France, serving clients all around the world.